Compare General Mills, Inc. (GIS) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs McKesson Corporation — how do they compare? General Mills, Inc. trades at $38.94 (market cap $19.46B), while McKesson Corporation trades at $842.53 (market cap $93.23B). The key difference: McKesson Corporation is far larger — about 4.8× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.69%). Which is the better fit depends on your goals.
| GIS | MCK | |
|---|---|---|
Market Cap | $19.46B | $93.23B |
Sector | Consumer Staples | Health |
52-Week High | $51.27 | $995.69 |
52-Week Low | $32.17 | $659.01 |
Enterprise Value | $32.95B | $97.87B |
Dividend Yield | 6.69% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $38.95, up 6.83% in the last session, with a bullish technical signal from moving averages. The stock shows mixed earnings performance, beating estimates in Q3 2025 and Q2 2026 but missing in Q4 2025. Revenue declined to $19.49B in 2025, with net income margin turning negative at -0.48% for 2026. Recent news highlights partnerships in regenerative agriculture and cost-saving initiatives targeting $3 billion by 2030 to support margins amid soft demand.
The outlook is cautious; while valuation appears attractive with a P/E of 9.23, weak sales and profit pressure pose risks. Analyst consensus is mixed with 22.22% buy ratings, but the average price target of $36.14 suggests limited upside. Key risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
MCK trades at $836.49, up 4.12% in the last session, with a neutral technical signal and strong analyst consensus. Recent earnings consistently beat expectations, with Q1 2026 EPS of $11.69 surpassing the $11.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins remain thin at 1.18%. The stock is supported by positive cash flow trends and a dividend payout scheduled for July 2026.
The outlook is positive, driven by earnings momentum and a $932.83 consensus price target implying 11.5% upside. Risks include low profitability margins and high liabilities, but institutional sentiment is bullish with 80% buy ratings. Investors should weigh growth in specialty pharma against execution and regulatory pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
